Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed 19 clinical trials and found that dermatologic adverse events, such as rash, xerosis, and mucositis, frequently occur in pediatric patients receiving targeted anticancer therapies.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

This review highlights that dermatologic side effects of cancer therapies, such as chemotherapy and immunotherapy, are increasingly complex, emphasizing the importance of preventive and management strategies to reduce skin toxicity and improve treatment adherence.

This review discusses common skin toxicities from cancer treatments and offers management strategies, particularly for regions like Australia and New Zealand with high UV exposure.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This review discusses the repurposing of auranofin for oncological and non-oncological uses and highlights its early-stage clinical trial findings, suggesting further exploration of its therapeutic potential.

This case report describes a 61-year-old woman with telogen effluvium, highlighting her concerns about exacerbated hair loss after surgery and aims to explore anesthesia techniques that might reduce hair shedding in such patients.

This source does not report original research findings but reviews the mechanisms and challenges of immune response and immunosuppressive management in liver transplantation.

This article reviews the challenges and treatment options for pancreatic cancer, emphasizing the need for a collaborative care approach due to the disease's advanced presentation and poor prognosis; it reports no new clinical findings.

This article discusses ethical concerns in medicine around high physician incomes and the rush to adopt expensive technologies like proton beam therapy without clear clinical benefits, without reporting new research findings.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This article reviews potential factors contributing to hair loss in androgenetic alopecia beyond genetic predispositions and discusses current knowledge without presenting new clinical results.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study found that inhibiting AP-1 activity in mice modified tumor development, leading to transdifferentiation between squamous and sebaceous tumors, with molecular analysis suggesting AP-1's role in maintaining tumor cell identity.

This study reported that the combination of tridax procumbens and ginger juice improved antioxidant activity and protected against liver damage induced by paracetamol in rats, suggesting a potent hepatoprotective effect.

In this study, researchers used a computational drug repurposing approach to identify FDA-approved drugs Dutasteride and Solifenacin as potential inhibitors of Listeria monocytogenes via binding to the virulence factor regulator PrfA, suggesting they may offer new treatment strategies against multi-drug resistant strains.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

This study suggests that pretreatment with a PPAR-γ modulator may prevent damage to hair follicle stem cells caused by a chemotherapy metabolite, potentially offering a strategy to mitigate permanent chemotherapy-induced alopecia.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

This study presents a computational approach, CATNIP, which repurposes drugs using only their biological and chemical information, predicting new uses like adrenergic uptake inhibitors for Parkinson's and vandetanib for Type 2 Diabetes.

This study observed that valproic acid treatment led to a significant reduction in aggressive and impulsive behaviors among patients with acquired brain injury, with varying effects based on cognitive impairment degree; the treatment was generally well-tolerated, though some patients experienced temporary side effects.